Quintrio
Home

MISCELLANEOUS CHEMICAL PRODUCTS

ASP Isotopes Inc. Common Stock

ASPI

ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Currently, the company has three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) construction services. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.

Last trade $1.39
Day change -$0.155 (-10.06%)
Day range $1.37 – $1.64
Volume 3,118,916
Market cap $236M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$236.1M
Price / earnings
—
Price / book
0.89×
Price / sales
7.65×
EV / sales
9.08×
EV / EBITDA
-2.99×

Profitability

Earnings per share
-$0.86
Return on assets
-23.08%
Return on equity
-49.89%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1×
Current ratio
3.87×
Quick ratio
3.85×
Cash ratio
3.12×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$83.58M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ASPI, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$5.12M$4.18M$16.66M$4.89M$1.2M$1.1M$1.19M$1.09M
Cost of revenue$3.64M$2.51M$14.58M$4.47M$626K$775K$588.53K$793.71K
Gross profit$1.48M$1.67M$2.08M$423.18K$572K$327K$605.13K$293.98K
Selling, general and administrative$28.85M$21.29M$17.54M$12.29M$11.66M$6.75M$6.84M$4.69M
Research and development$6.82M$5.26M$9.57M$3.1M$880K$1.53M$1.42M$1.03M
Total operating expenses$35.68M$26.55M$27.1M$15.39M$12.54M$8.28M$8.25M$5.73M
Operating income-$34.2M-$24.89M-$25.02M-$14.97M-$11.97M-$7.95M-$7.65M-$5.43M
Interest expense-$1.77M-$1.73M-$259.99K-$146.06K-$82K-$87K-$85.17K-$90.97K
Income before taxes-$34.09M-$26.74M-$63.15M-$12.82M-$75.06M-$8.53M-$9.07M-$7.36M
Income taxes-$97K-$31K$183.85K$73.63K$95K-$71K$153.22K-$8.37K
Net income-$33.99M-$26.71M-$63.33M-$12.89M-$75.16M-$8.46M-$9.22M-$7.36M
Net income attributable to common shareholders-$33.59M-$6.88M-$78.71M-$12.87M-$75.06M-$8.45M-$9.18M-$7.27M
EBITDA-$32.99M-$21.83M-$24.08M-$14.67M-$11.44M-$7.8M-$7.6M-$5.26M
Basic earnings per share-$0.27-$0.06-$0.78-$0.15-$1.03-$0.12-$0.14-$0.12
Diluted earnings per share-$0.27-$0.06-$0.78-$0.15-$1.03-$0.12-$0.14-$0.12

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

ASP Isotopes Announces Agreements to Exchange Certain QLE Convertible Notes for ASPI Common Stock

ASP Isotopes announced that it and its subsidiary Quantum Leap Energy (QLE) have entered into exchange agreements with certain convertible note holders. Approximately $109.2 million in QLE Notes will be exchanged for roughly 23.2 million shares of ASPI common stock, reducing QLE's outstanding convertible notes by approximately 50% from $219.8 million to $110.7 million. The transaction is intended to strengthen QLE's balance sheet and simplify its capital structure as it pursues a separate public listing.

GlobeNewswire Inc.

Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Integer Holdings Corp. (NYSE: ITGR); Molina Healthcare, Inc. (NYSE: MOH); and Soleno Therapeutics, Inc. (NASDAQ: SLNO): Grabar Law Office Investigates Claims on Your Behalf

Grabar Law Office is investigating securities fraud claims against four companies: ASP Isotopes for allegedly making false statements about uranium enrichment technology; Integer Holdings for overstating competitive position and concealing sales deterioration; Molina Healthcare for failing to disclose adverse medical cost trends; and Soleno Therapeutics for misrepresenting the safety profile of its drug candidate DCCR, which resulted in a patient death.

GlobeNewswire Inc.

Important Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Integer Holdings Corp. (NYSE: ITGR): Soleno Therapeutics, Inc. (NASDAQ: SLNO); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office is investigating securities fraud claims against four companies: ASP Isotopes for allegedly making false statements about uranium enrichment technology; Integer Holdings for overstating competitive position and concealing sales deterioration; Soleno Therapeutics for misrepresenting safety profile of drug candidate DCCR/VYKAT XR; and Unicycive Therapeutics for overstating FDA manufacturing compliance readiness. Shareholders who purchased shares during specified periods may be eligible to seek corporate reforms and compensation.

GlobeNewswire Inc.

Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Camping World Holdings, Inc. (NYSE: CWH); EOS Energy Enterprise, Inc. (NASDAQ: EOSE); and Soleno Therapeutics, Inc. (NASDAQ: SLNO): Grabar Law Office Investigates Claims on Your Behalf

Grabar Law Office is investigating securities fraud claims against four companies: ASP Isotopes (ASPI) for allegedly making false statements about uranium enrichment technology; Camping World (CWH) for misrepresenting inventory management and financial outlook; EOS Energy (EOSE) for failing to disclose production challenges and operational issues; and Soleno Therapeutics (SLNO) for concealing safety concerns about its drug candidate DCCR/VYKAT XR. Long-term shareholders may seek corporate reforms and compensation at no cost.

Benzinga

Shorepower Technologies (OTC: SPEV) Enters Merger Agreement with Aeternum Health LLC and Announces Strategic Transition to Longevity-Focused Healthcare Platform

Shorepower Technologies (OTC: SPEV) has entered into a merger agreement with Aeternum Health LLC, marking a strategic pivot from transportation electrification infrastructure to longevity and health optimization technologies. The merger involves issuing 51% common stock ownership to Aeternum Health's sole member, 2 million Series B Preferred Shares, and a minimum $1.5 million cash contribution. Paul E. Mann, CEO of ASP Isotopes (NASDAQ: ASPI), will become the new CEO of Shorepower upon closing. The company plans to spin out its existing transportation electrification business and change its corporate name to Aeternum Health Inc.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.